<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fresenius Medical Care Ag & Co. Kgaa — News on 6ix</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa</link>
<description>Latest news and press releases for Fresenius Medical Care Ag & Co. Kgaa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Feb 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fresenius-medical-care-ag-and-co-kgaa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836045a78dffbe2df135783.webp</url>
<title>Fresenius Medical Care Ag & Co. Kgaa</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa</link>
</image>
<item>
<title>Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-delivers-27percent-earnings-growth-in-2025-and-reaches-upper-end-of-its-financial-outlook-margin-within-2025-mid-term-target-band</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-delivers-27percent-earnings-growth-in-2025-and-reaches-upper-end-of-its-financial-outlook-margin-within-2025-mid-term-target-band</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>"Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025. These achievements reflect our disciplined focus on operational and financial excellence. In 2025, we delivered revenue and operating income growth at the upper end of our outlook, overcoming a difficult market environment," said Helen</description>
</item>
<item>
<title>Interwell Health Appoints Dr. Carney Taylor as Chief Medical Officer</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/interwell-health-appoints-dr-carney-taylor-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/interwell-health-appoints-dr-carney-taylor-as-chief-medical-officer</guid>
<pubDate>Mon, 26 Jan 2026 14:30:00 GMT</pubDate>
<description>Interwell Health, a national leader in value-based kidney care and operating segment of Fresenius Medical Care, has named Carney Taylor, MD, MBA, as chief medical officer to guide clinical strategy, physician engagement, and quality initiatives. The appointment is part of the company's succession plan for Dr. George Hart, who retired as CMO on January 1 and will remain with Interwell in a strategic advisory role to support a seamless transition.</description>
</item>
<item>
<title>Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned</guid>
<pubDate>Fri, 09 Jan 2026 12:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January 12 to May 8, 2026.</description>
</item>
<item>
<title>Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-appoints-charles-hugh-jones-as-global-chief-medical-officer-and-member-of-the-management-board</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-appoints-charles-hugh-jones-as-global-chief-medical-officer-and-member-of-the-management-board</guid>
<pubDate>Wed, 10 Dec 2025 13:00:00 GMT</pubDate>
<description>The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer.</description>
</item>
<item>
<title>Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-further-accelerates-organic-revenue-development-and-achieves-an-inflection-in-earnings-growth-delivering-28percent-operating-income-growth-in-the-third-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-further-accelerates-organic-revenue-development-and-achieves-an-inflection-in-earnings-growth-delivering-28percent-operating-income-growth-in-the-third-quarter-of-2025</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>"In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income2 margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of</description>
</item>
<item>
<title>Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-highlights-real-world-advances-in-hemodiafiltration-and-ai-at-asn-kidney-week-2025</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-highlights-real-world-advances-in-hemodiafiltration-and-ai-at-asn-kidney-week-2025</guid>
<pubDate>Thu, 30 Oct 2025 13:00:00 GMT</pubDate>
<description>Fresenius Medical Care AG (FME), the world's leading provider of products and services for people with kidney diseases, will present new research showing how hemodiafiltration (HDF) is associated with improved outcomes for kidney patients and how innovations in artificial intelligence (AI) can support clinicians in daily care at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston.</description>
</item>
<item>
<title>Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-appoints-joseph-turk-as-new-management-board-member-for-care-enablement</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-appoints-joseph-turk-as-new-management-board-member-for-care-enablement</guid>
<pubDate>Wed, 01 Oct 2025 13:35:00 GMT</pubDate>
<description>The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.</description>
</item>
<item>
<title>Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-advances-its-fme-reignite-strategy-by-increasing-ownership-in-its-value-based-care-asset-and-appointing-a-new-leader-for-the-operating-segment</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-advances-its-fme-reignite-strategy-by-increasing-ownership-in-its-value-based-care-asset-and-appointing-a-new-leader-for-the-operating-segment</guid>
<pubDate>Thu, 18 Sep 2025 19:30:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced several important developments in its Value-Based Care (VBC) operating segment, reinforcing its commitment to delivering high-quality, cost-effective care for patients with kidney disease.</description>
</item>
<item>
<title>Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-announces-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million-as-part-of-its-new-capital-allocation-framework</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-announces-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million-as-part-of-its-new-capital-allocation-framework</guid>
<pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.</description>
</item>
<item>
<title>Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/quest-diagnostics-completes-acquisition-of-clinical-testing-assets-from-fresenius-medical-care-1</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/quest-diagnostics-completes-acquisition-of-clinical-testing-assets-from-fresenius-medical-care-1</guid>
<pubDate>Tue, 05 Aug 2025 12:33:00 GMT</pubDate>
<description>Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of Fresenius Medical Care's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the United States. With this acquisition, Quest will be positioned to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra Labor</description>
</item>
<item>
<title>Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-delivers-strong-organic-revenue-growth-and-double-digit-operating-income-growth-in-the-second-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-delivers-strong-organic-revenue-growth-and-double-digit-operating-income-growth-in-the-second-quarter-of-2025</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>"In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth and double-digit operating income growth put us fully on track to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Organic revenue growth of 7% was supported by all operating segments. The overall phasing of earnings in the first half of the year developed in line with our planning. Strong profitability gains in Car</description>
</item>
<item>
<title>Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/azenta-life-sciences-partners-with-frenova-a-division-of-fresenius-medical-care-and-nephronomics-to-advance-genomic-research-in-nephrology</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/azenta-life-sciences-partners-with-frenova-a-division-of-fresenius-medical-care-and-nephronomics-to-advance-genomic-research-in-nephrology</guid>
<pubDate>Thu, 31 Jul 2025 20:05:00 GMT</pubDate>
<description>Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients world</description>
</item>
<item>
<title>Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-cares-third-party-clinical-research-organization-frenova-announces-strategic-collaboration-advancing-genomics-driven-precision-kidney-disease-care</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-cares-third-party-clinical-research-organization-frenova-announces-strategic-collaboration-advancing-genomics-driven-precision-kidney-disease-care</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis efforts for Frenova's transformative My Reason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to better understand kidney, cardiovascular, and metabolic diseases while driving a</description>
</item>
<item>
<title>Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-collaborates-with-coordination-of-national-institutes-of-health-and-specialty-hospital-to-extend-access-to-innovative-dialysis-therapy-in-mexico</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-collaborates-with-coordination-of-national-institutes-of-health-and-specialty-hospital-to-extend-access-to-innovative-dialysis-therapy-in-mexico</guid>
<pubDate>Thu, 03 Jul 2025 12:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies.</description>
</item>
<item>
<title>Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/opterion-health-ag-appoints-industry-leaders-rice-powell-and-mark-hahn-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/opterion-health-ag-appoints-industry-leaders-rice-powell-and-mark-hahn-to-board-of-directors</guid>
<pubDate>Mon, 23 Jun 2025 06:00:00 GMT</pubDate>
<description>MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the appointment of two highly accomplished executives to its Board of Directors: Rice Powell, former Chairman and CEO of Fresenius Medical Care, and Mark Hahn, Chief Financial Officer of Verona Pharma and a veteran biotech finance leader. These appointments represent a significant step fo</description>
</item>
<item>
<title>Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-launches-its-strategy-fme-reignite-with-increased-profitability-aspirations-and-a-new-capital-allocation-framework-to-further-enhance-value-creation</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-launches-its-strategy-fme-reignite-with-increased-profitability-aspirations-and-a-new-capital-allocation-framework-to-further-enhance-value-creation</guid>
<pubDate>Tue, 17 Jun 2025 11:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, today unveiled its new FME Reignite strategy at its Capital Markets Day in London. FME Reignite centers on value creation, based on three strategic elements: Reignite the core, Reignite growth and innovation and Reignite our culture.</description>
</item>
<item>
<title>Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-begins-broader-us-commercialization-of-5008xtm-caresystem-achieves-key-milestones-in-efforts-to-introduce-high-volume-hemodiafiltration-dialysis-therapy-to-individuals-with-kidney-disease-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-begins-broader-us-commercialization-of-5008xtm-caresystem-achieves-key-milestones-in-efforts-to-introduce-high-volume-hemodiafiltration-dialysis-therapy-to-individuals-with-kidney-disease-in-the-us</guid>
<pubDate>Wed, 04 Jun 2025 12:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broade</description>
</item>
<item>
<title>Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-presents-its-new-research-and-innovation-for-kidney-care-at-european-renal-association-congress-2025</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-presents-its-new-research-and-innovation-for-kidney-care-at-european-renal-association-congress-2025</guid>
<pubDate>Fri, 30 May 2025 12:00:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, presents new research and innovations at the 62nd Congress of the European Renal Association (ERA), June 4-7 in Vienna, Austria highlighting the company's growing emphasis on data-driven insights and real-world evidence to advance patient care and improve outcomes and quality of life for people with kidney disease worldwide.</description>
</item>
<item>
<title>Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-annual-general-meeting-strong-performance-against-its-strategic-plan-results-in-highest-dividend-per-share-in-its-history</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-annual-general-meeting-strong-performance-against-its-strategic-plan-results-in-highest-dividend-per-share-in-its-history</guid>
<pubDate>Thu, 22 May 2025 15:45:00 GMT</pubDate>
<description>Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, continuously executed its strategic plan during the 2024 fiscal year. The success of this transformation is strengthening the foundation for sustainable, profitable growth — both now and in the future.</description>
</item>
<item>
<title>Fresenius Medical Care starts 2025 with strong organic revenue and income growth</title>
<link>https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-starts-2025-with-strong-organic-revenue-and-income-growth</link>
<guid isPermaLink="true">https://6ix.com/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-starts-2025-with-strong-organic-revenue-and-income-growth</guid>
<pubDate>Tue, 06 May 2025 11:00:00 GMT</pubDate>
<description>"The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Revenue of both segments grew organically, and the phasing of the operating income development was in-line with our expectations. Care Enablement executed strongly against its transformation plan and further expanded its operating income ma</description>
</item>
</channel>
</rss>